243 related articles for article (PubMed ID: 15717947)
1. Intensity-modulated radiotherapy: is xerostomia still prevalent?
Chambers MS; Garden AS; Rosenthal D; Ahamad A; Schwartz DL; Blanco AI; Chao KS; Morrison WH; Ang KK; Weber RS
Curr Oncol Rep; 2005 Mar; 7(2):131-6. PubMed ID: 15717947
[TBL] [Abstract][Full Text] [Related]
2. Intensity-modulated radiation therapy and xerostomia.
Chambers MS; Weber RS; Garden AS
J Calif Dent Assoc; 2006 Sep; 34(9):743-8. PubMed ID: 17022299
[TBL] [Abstract][Full Text] [Related]
3. Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer.
Eisbruch A; Ship JA; Dawson LA; Kim HM; Bradford CR; Terrell JE; Chepeha DB; Teknos TN; Hogikyan ND; Anzai Y; Marsh LH; Ten Haken RK; Wolf GT
World J Surg; 2003 Jul; 27(7):832-7. PubMed ID: 14509515
[TBL] [Abstract][Full Text] [Related]
4. Recovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated Radiotherapy.
Miah AB; Gulliford SL; Morden J; Newbold KL; Bhide SA; Zaidi SH; Hall E; Harrington KJ; Nutting CM
Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e69-e76. PubMed ID: 26994893
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy.
Münter MW; Karger CP; Hoffner SG; Hof H; Thilmann C; Rudat V; Nill S; Wannenmacher M; Debus J
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):175-84. PubMed ID: 14697436
[TBL] [Abstract][Full Text] [Related]
6. Comparison of xerostomia incidence after three-dimensional conformal radiation therapy and contralateral superficial lobe parotid-sparing intensity-modulated radiotherapy for oropharyngeal and hypopharyngeal cancer.
Kawamoto T; Nihei K; Nakajima Y; Kito S; Sasai K; Karasawa K
Auris Nasus Larynx; 2018 Oct; 45(5):1073-1079. PubMed ID: 29397249
[TBL] [Abstract][Full Text] [Related]
7. Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study.
Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Tu WY; Kirwan J; Mendenhall WM
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1479-87. PubMed ID: 20934262
[TBL] [Abstract][Full Text] [Related]
8. Using a reduced spot size for intensity-modulated proton therapy potentially improves salivary gland-sparing in oropharyngeal cancer.
van de Water TA; Lomax AJ; Bijl HP; Schilstra C; Hug EB; Langendijk JA
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e313-9. PubMed ID: 21708427
[TBL] [Abstract][Full Text] [Related]
9. Intensity-modulated radiotherapy or volumetric-modulated arc therapy in patients with head and neck cancer: Focus on salivary glands dosimetry.
Vallard A; Guy JB; Mengue Ndong S; Vial N; Rivoirard R; Auberdiac P; Méry B; Langrand-Escure J; Espenel S; Moncharmont C; Ben Mrad M; Diao P; Goyet D; Magné N
Head Neck; 2016 Jul; 38(7):1028-34. PubMed ID: 26855006
[TBL] [Abstract][Full Text] [Related]
10. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results.
Chao KS; Deasy JO; Markman J; Haynie J; Perez CA; Purdy JA; Low DA
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):907-16. PubMed ID: 11240231
[TBL] [Abstract][Full Text] [Related]
11. Can dose reduction to one parotid gland prevent xerostomia?--A feasibility study for locally advanced head and neck cancer patients treated with intensity-modulated radiotherapy.
Anand AK; Jain J; Negi PS; Chaudhoory AR; Sinha SN; Choudhury PS; Kumar R; Munjal RK
Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):497-504. PubMed ID: 16909975
[TBL] [Abstract][Full Text] [Related]
12. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
[TBL] [Abstract][Full Text] [Related]
13. Xerostomia, salivary characteristics and gland volumes following intensity-modulated radiotherapy for nasopharyngeal carcinoma: a two-year follow up.
Sim C; Soong YL; Pang E; Lim C; Walker GD; Manton DJ; Reynolds EC; Wee J
Aust Dent J; 2018 Jun; 63(2):217-223. PubMed ID: 29569726
[TBL] [Abstract][Full Text] [Related]
14. Changes in salivary gland function after radiotherapy of head and neck tumors measured by quantitative pertechnetate scintigraphy: comparison of intensity-modulated radiotherapy and conventional radiation therapy with and without Amifostine.
Münter MW; Hoffner S; Hof H; Herfarth KK; Haberkorn U; Rudat V; Huber P; Debus J; Karger CP
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):651-9. PubMed ID: 17175118
[TBL] [Abstract][Full Text] [Related]
15. Sparing all salivary glands with IMRT for head and neck cancer: Longitudinal study of patient-reported xerostomia and head-and-neck quality of life.
Hawkins PG; Lee JY; Mao Y; Li P; Green M; Worden FP; Swiecicki PL; Mierzwa ML; Spector ME; Schipper MJ; Eisbruch A
Radiother Oncol; 2018 Jan; 126(1):68-74. PubMed ID: 28823405
[TBL] [Abstract][Full Text] [Related]
16. Reducing xerostomia after chemo-IMRT for head-and-neck cancer: beyond sparing the parotid glands.
Little M; Schipper M; Feng FY; Vineberg K; Cornwall C; Murdoch-Kinch CA; Eisbruch A
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):1007-14. PubMed ID: 22056067
[TBL] [Abstract][Full Text] [Related]
17. Compensator-based intensity-modulated radiotherapy in head and neck cancer: our experience in achieving dosimetric parameters and their clinical correlation.
Nangia S; Chufal KS; Arivazhagan V; Srinivas P; Tyagi A; Ghosh D
Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):485-92. PubMed ID: 16909973
[TBL] [Abstract][Full Text] [Related]
18. 3D-conformal-intensity modulated radiotherapy with compensators for head and neck cancer: clinical results of normal tissue sparing.
Wendt TG; Abbasi-Senger N; Salz H; Pinquart I; Koscielny S; Przetak SM; Wiezorek T
Radiat Oncol; 2006 Jun; 1():18. PubMed ID: 16790059
[TBL] [Abstract][Full Text] [Related]
19. Target volume definition for head and neck intensity modulated radiotherapy: pre-clinical evaluation of PARSPORT trial guidelines.
Guerrero Urbano MT; Clark CH; Kong C; Miles E; Dearnaley DP; Harrington KJ; Nutting CM; PARSPORT Trial Management Group
Clin Oncol (R Coll Radiol); 2007 Oct; 19(8):604-13. PubMed ID: 17706404
[TBL] [Abstract][Full Text] [Related]
20. Submandibular gland-sparing radiation therapy for locally advanced oropharyngeal squamous cell carcinoma: patterns of failure and xerostomia outcomes.
Gensheimer MF; Liao JJ; Garden AS; Laramore GE; Parvathaneni U
Radiat Oncol; 2014 Nov; 9():255. PubMed ID: 25424729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]